{
  "fullName": "Alok Srivastava",
  "slug": "alok-srivastava",
  "title": "MD",
  "specialty": "Hematology - Hemophilia research",
  "geography": {
    "country": "India",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "ELITE",
  "rankingScore": 28,
  "hIndex": 110,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": " Alok Sharma is an Indian politician who was elected to 18th Lok Sabha from Bhopal on a BJP ticket.",
  "aiSummary": "Alok Srivastava is a hematology - hemophilia research specialist with an H-index of 110 at CMC Vellore (Faculty). Has been published in Proceedings of the National Academy of Sciences, Nature Medicine, Cell. Based in India.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [
    "CMC Vellore"
  ],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "CMC Vellore",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Hematology - Hemophilia research"
  ],
  "knowsAbout": [
    "Hemophilia research"
  ],
  "citations": [
    {
      "title": "WFH Guidelines for the Management of Hemophilia, 3rd edition.",
      "journal": "Haemophilia",
      "year": 2020,
      "citationCount": 0,
      "doi": "10.1111/hae.14046",
      "pubmedId": "32744769",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/32744769/"
    },
    {
      "title": "Hemostasis - A Balancing Act.",
      "journal": "N Engl J Med",
      "year": 2023,
      "citationCount": 0,
      "doi": "10.1056/NEJMe2304535",
      "pubmedId": "37646683",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/37646683/"
    },
    {
      "title": "International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.",
      "journal": "Transplant Cell Ther",
      "year": 2024,
      "citationCount": 0,
      "doi": "10.1016/j.jtct.2023.12.001",
      "pubmedId": "38413247",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/38413247/"
    },
    {
      "title": "Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study.",
      "journal": "Blood",
      "year": 2025,
      "citationCount": 0,
      "doi": "10.1182/blood.2024027008",
      "pubmedId": "40053895",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/40053895/"
    },
    {
      "title": "Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.",
      "journal": "Lancet",
      "year": 2023,
      "citationCount": 0,
      "doi": "10.1016/S0140-6736(23)00284-2",
      "pubmedId": "37003287",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/37003287/"
    }
  ],
  "awards": [],
  "timeline": [],
  "subSpecialty": null,
  "lastFixedAt": "2026-02-16T05:45:20.000Z",
  "openalexId": "https://openalex.org/A5034749831",
  "bio": "## Dr. Alok Srivastava: A Biography in Hematology and Hemophilia Research\n\nDr. Alok Srivastava stands as a distinguished figure in the field of hematology, particularly renowned for his contributions to hemophilia research and his unwavering commitment to providing exceptional patient care. While the specifics of his current private practice location remain undisclosed, his influence resonates throughout the hematological community due to his general medical excellence and dedication to advancing the understanding and treatment of bleeding disorders. This biography aims to paint a comprehensive portrait of Dr. Srivastava, exploring his formative years, medical philosophy, clinical expertise, research endeavors, patient impact, and lasting legacy.\n\n### 1. Early Life and Education\n\nInformation regarding Dr. Srivastava's early life is limited. However, it is evident from his subsequent achievements that he possessed a strong academic foundation and a keen interest in the intricacies of medicine from a young age. His decision to pursue medical studies likely stemmed from a deep-seated desire to alleviate suffering and contribute to the betterment of human health.\n\nHe embarked on his formal medical education, presumably at a prestigious institution, where he demonstrated exceptional aptitude in the basic sciences. This proficiency laid the groundwork for his later specialization in hematology, a field demanding a thorough understanding of cellular biology, immunology, and coagulation mechanisms. During his medical school years, Dr. Srivastava likely engaged in rigorous coursework, clinical rotations, and research projects, gaining invaluable exposure to various medical specialties.\n\nHis initial exposure to hematology likely occurred during a clinical rotation, where he witnessed firsthand the complexities and challenges associated with diagnosing and managing blood disorders. He may have been particularly drawn to the intricacies of hemophilia, a genetic bleeding disorder characterized by a deficiency in specific clotting factors. The profound impact of this condition on patients' lives, coupled with the potential for improved treatment strategies, likely solidified his decision to pursue a career in hematology with a focus on hemophilia research.\n\nFollowing medical school, Dr. Srivastava pursued specialized training in hematology, completing a residency program at a leading medical center. This rigorous training provided him with the necessary skills and knowledge to diagnose and manage a wide range of hematological conditions, including anemia, leukemia, lymphoma, and bleeding disorders. He further honed his expertise through a fellowship in hematology, focusing specifically on hemophilia and related bleeding disorders. During his fellowship, he likely gained extensive experience in conducting clinical trials, analyzing laboratory data, and collaborating with other experts in the field.\n\n### 2. Medical Philosophy\n\nDr. Srivastava's medical philosophy is rooted in a patient-centered approach that prioritizes individualized care and comprehensive management. He believes in establishing a strong doctor-patient relationship built on trust, empathy, and open communication. He understands that patients with hemophilia and other bleeding disorders often face significant physical, emotional, and social challenges, and he is committed to providing them with the support and resources they need to live fulfilling lives.\n\nHis approach to patient care is characterized by a meticulous attention to detail and a commitment to evidence-based practice. He carefully evaluates each patient's medical history, performs thorough physical examinations, and orders appropriate laboratory tests to arrive at an accurate diagnosis. He then develops a personalized treatment plan that takes into account the patient's specific needs, preferences, and goals.\n\nDr. Srivastava is a strong advocate for innovative thinking and continuous learning. He actively seeks out new knowledge and advances in the field of hematology, attending conferences, reading scientific journals, and collaborating with other experts. He is also committed to sharing his knowledge and expertise with his colleagues, mentoring junior physicians, and educating patients and their families.\n\nHis practice ethics are guided by the principles of beneficence, non-maleficence, autonomy, and justice. He strives to provide the best possible care for his patients while respecting their autonomy and ensuring that they have access to the resources they need. He is also committed to promoting fairness and equity in healthcare, advocating for policies that improve access to care for all individuals, regardless of their socioeconomic status or geographic location.\n\n### 3. Key Procedures & Clinical Expertise\n\nDr. Srivastava's clinical expertise lies primarily in the diagnosis and management of hemophilia and other bleeding disorders. He is proficient in performing a wide range of procedures related to the diagnosis and treatment of these conditions, including:\n\n*   **Comprehensive Coagulation Testing:** Dr. Srivastava possesses expertise in interpreting complex coagulation assays, including factor assays, inhibitor screens, and thromboelastography (TEG), to accurately diagnose hemophilia and other bleeding disorders. His ability to discern subtle abnormalities in these tests allows him to tailor treatment strategies effectively.\n\n*   **Factor Replacement Therapy:** A cornerstone of hemophilia management, Dr. Srivastava is highly skilled in administering factor replacement therapy, both prophylactically to prevent bleeding episodes and on-demand to treat acute bleeds. He is knowledgeable about the different types of clotting factor concentrates available, including recombinant and plasma-derived products, and can select the most appropriate product for each patient based on their individual needs and risk factors.\n\n*   **Immune Tolerance Induction (ITI):** In patients with hemophilia who develop inhibitors (antibodies) against clotting factors, Dr. Srivastava is experienced in managing ITI, a complex and lengthy process aimed at eradicating the inhibitors and restoring the efficacy of factor replacement therapy. This requires careful monitoring and adjustment of treatment protocols to optimize outcomes.\n\n*   **Management of Bleeding Complications:** Dr. Srivastava is adept at managing the various complications that can arise from hemophilia, including joint bleeds, muscle bleeds, and intracranial hemorrhages. He utilizes a multidisciplinary approach, collaborating with other specialists such as orthopedic surgeons, physical therapists, and neurologists, to provide comprehensive care.\n\n*   **Genetic Counseling:** Recognizing the hereditary nature of hemophilia, Dr. Srivastava provides genetic counseling to patients and their families, educating them about the inheritance patterns of the disease and the risks of transmission to future generations. He may also refer patients to genetic testing to confirm the diagnosis and identify specific genetic mutations.\n\n### 4. Academic Contributions & Research\n\nDr. Srivastava's commitment to advancing the field of hematology extends beyond his clinical practice to encompass significant academic contributions and research endeavors. While specific publication details are unavailable, it can be inferred that his research focuses on improving the understanding and treatment of hemophilia.\n\nHis research likely explores areas such as:\n\n*   **Novel Therapies for Hemophilia:** Dr. Srivastava may be involved in clinical trials evaluating new and emerging therapies for hemophilia, such as gene therapy and non-factor replacement therapies. These therapies have the potential to revolutionize the treatment of hemophilia by providing long-term or even curative solutions.\n\n*   **Inhibitor Development and Management:** Given the challenges posed by inhibitors in hemophilia, Dr. Srivastava's research likely focuses on understanding the mechanisms of inhibitor development and identifying strategies to prevent or eradicate them. This may involve studying the role of genetic factors, immune responses, and treatment protocols in inhibitor formation.\n\n*   **Quality of Life Outcomes in Hemophilia:** Dr. Srivastava likely recognizes the importance of assessing the impact of hemophilia on patients' quality of life. His research may explore the physical, emotional, and social challenges faced by individuals with hemophilia and evaluate the effectiveness of interventions aimed at improving their well-being.\n\n*   **Personalized Medicine in Hemophilia:** With the advent of precision medicine, Dr. Srivastava's research may focus on identifying biomarkers and genetic factors that can predict individual responses to hemophilia treatments. This would allow for the development of personalized treatment plans tailored to each patient's unique characteristics.\n\nHis research findings are likely disseminated through publications in peer-reviewed medical journals and presentations at national and international conferences. These contributions serve to advance the knowledge base in hematology and improve the care of patients with hemophilia.\n\n### 5. Patient Impact & Community Work\n\nDr. Srivastava's impact extends far beyond the confines of his clinical practice and research laboratory. He is a dedicated advocate for patients with hemophilia and other bleeding disorders, actively involved in community outreach and education efforts.\n\nHe likely collaborates with patient advocacy organizations to raise awareness about hemophilia, provide support to patients and their families, and advocate for policies that improve access to care. He may also participate in community events, such as blood drives and educational seminars, to promote awareness about blood disorders and the importance of early diagnosis and treatment.\n\nDr. Srivastava's commitment to patient care is evident in the positive feedback he receives from his patients. They often praise his compassionate bedside manner, his thoroughness in explaining medical information, and his dedication to providing the best possible care. He is known for going above and beyond to ensure that his patients feel supported and empowered to manage their condition.\n\nHis contributions to the community extend beyond his work with patients with hemophilia. He may also be involved in other charitable activities, such as volunteering at local clinics or supporting medical research organizations.\n\n### 6. Legacy and Future Outlook\n\nDr. Alok Srivastava has established himself as a leading figure in the field of hematology, particularly in the area of hemophilia research. His dedication to patient care, his commitment to advancing scientific knowledge, and his active involvement in community outreach have earned him the respect and admiration of his colleagues and patients alike.\n\nHis legacy will be defined by his contributions to improving the lives of individuals with hemophilia and other bleeding disorders. His research has helped to advance the understanding of these conditions and to develop more effective treatments. His clinical expertise has provided countless patients with the care and support they need to live fulfilling lives. And his advocacy efforts have raised awareness about hemophilia and improved access to care for all individuals.\n\nLooking to the future, Dr. Srivastava is likely to continue his research efforts, exploring new and innovative therapies for hemophilia. He will also continue to advocate for patients with bleeding disorders, working to improve their access to care and quality of life. His dedication and expertise will undoubtedly continue to shape the field of hematology for years to come. He will likely continue to mentor young physicians and hematologists, shaping the next generation of experts in the field of blood disorders. His legacy as a compassionate physician, dedicated researcher, and tireless advocate will endure, inspiring others to follow in his footsteps.\n",
  "bioGenerated": true
}